A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment

被引：0
|
作者：
Nikol Snoeren
Emile E Voest
Andre M Bergman
Otilia Dalesio
Henk M Verheul
Rob AEM Tollenaar
Joost RM van der Sijp
Sander B Schouten
Inne HM Borel Rinkes
R van Hillegersberg
机构：
[1] University Medical Center Utrecht,Department of Surgical Oncology
[2] University Medical Center Utrecht,Department of Medical Oncology
[3] Antonie van Leeuwenhoek Hospital,Department of Medical Oncology
[4] Antonie van Leeuwenhoek Hospital,Department of Biometrics
[5] VU Medical Center De Boelelaan 1117,Department of Medical Oncology
[6] Department of Surgery,undefined
[7] Leiden,undefined
[8] Department of Surgery,undefined
来源：
BMC Cancer | / 10卷
关键词：
Vascular Endothelial Growth Factor; Bevacizumab; Liver Metastasis; Disease Free Survival; Oxaliplatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 29 条
  • [21] Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged > 70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
    Vamvakas, Lambros
    Matikas, Alexios
    Karampeazis, Athanasios
    Hatzidaki, Dora
    Kakolyris, Stelios
    Christophylakis, Charalampos
    Boukovinas, Ioannis
    Polyzos, Aris
    Georgoulias, Vassilis
    Souglakos, John
    BMC CANCER, 2014, 14
  • [22] A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer
    Cao, Ranhua
    Zhang, Shuai
    Ma, Dedong
    Hu, Likuan
    MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 5
  • [23] FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study)
    Mishima, Hideyuki
    Oba, Koji
    Sakamoto, Junichi
    Muro, Kei
    Yoshino, Takayuki
    Hyodo, Ichinosuke
    Maehara, Yoshihiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (02) : 134 - 138
  • [24] A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32)
    Kusano, Mitsuo
    Aoyama, Toru
    Okabayashi, Koji
    Hirata, Koichi
    Tsuji, Yasushige
    Nakamori, Shoji
    Asahara, Toshimasa
    Ohashi, Yasuo
    Yoshikawa, Takaki
    Sakamoto, Junichi
    Oba, Koji
    Saji, Shigetoyo
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 : S761 - S766
  • [25] A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation
    Liu, Yuguo
    Luan, Lijuan
    Wang, Xingli
    ONCOTARGETS AND THERAPY, 2015, 8 : 1061 - 1068
  • [26] A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer
    Ranhua Cao
    Shuai Zhang
    Dedong Ma
    Likuan Hu
    Medical Oncology, 2015, 32
  • [27] Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy
    Van Cutsem, Eric
    Joulain, Florence
    Hoff, Paulo M.
    Mitchell, Edith
    Ruff, Paul
    Lakomy, Radek
    Prausova, Jana
    Moiseyenko, Vladimir M.
    van Hazel, Guy
    Cunningham, David
    Arnold, Dirk
    Schmoll, Hans-Joachim
    ten Tije, Albert J.
    McKendrick, Joseph
    Kroening, Hendrik
    Humblet, Yves
    Gravalos, Cristina
    Le-Guennec, Solenn
    Andria, Michael
    Dochy, Emmanuelle
    Vishwanath, Raghu L.
    Macarulla, Teresa
    Tabernero, Josep
    TARGETED ONCOLOGY, 2016, 11 (03) : 383 - 400
  • [28] Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy
    Eric Van Cutsem
    Florence Joulain
    Paulo M. Hoff
    Edith Mitchell
    Paul Ruff
    Radek Lakomý
    Jana Prausová
    Vladimir M. Moiseyenko
    Guy van Hazel
    David Cunningham
    Dirk Arnold
    Hans-Joachim Schmoll
    Albert J. ten Tije
    Joseph McKendrick
    Hendrik Kröning
    Yves Humblet
    Cristina Grávalos
    Solenn Le-Guennec
    Michael Andria
    Emmanuelle Dochy
    Raghu L. Vishwanath
    Teresa Macarulla
    Josep Tabernero
    Targeted Oncology, 2016, 11 : 383 - 400
  • [29] A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naive patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial
    Nishikawa, Kazuhiro
    Murotani, Kenta
    Fujitani, Kazumasa
    Inagaki, Hitoshi
    Akamaru, Yusuke
    Tokunaga, Shinya
    Takagi, Masakazu
    Tamura, Shigeyuki
    Sugimoto, Naotoshi
    Shigematsu, Tadashi
    Yoshikawa, Takaki
    Ishiguro, Tohru
    Nakamura, Masato
    Hasegawa, Hiroko
    Morita, Satoshi
    Miyashita, Yumi
    Tsuburaya, Akira
    Sakamoto, Junichi
    Tsujinaka, Toshimasa
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (05) : 867 - 874
123